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Abstract
Kidney transplantation (KT) is often considered to be the method best able to restore fertility in a woman with chronic 
kidney disease (CKD). However, pregnancies in KT are not devoid of risks (in particular prematurity, small for gestational 
age babies, and the hypertensive disorders of pregnancy). An ideal profile of the potential KT mother includes “normal” or 
“good” kidney function (usually defined as glomerular filtration rate, GFR ≥ 60 ml/min), scant or no proteinuria (usually 
defined as below 500 mg/dl), normal or well controlled blood pressure (one drug only and no sign of end-organ damage), no 
recent acute rejection, good compliance and low-dose immunosuppression, without the use of potentially teratogen drugs 
(mycophenolic acid and m-Tor inhibitors) and an interval of at least 1–2 years after transplantation. In this setting, there is 
little if any risk of worsening of the kidney function. Less is known about how to manage “non-ideal” situations, such as a 
pregnancy a short time after KT, or one in the context of hypertension or a failing kidney. The aim of this position statement 
by the Kidney and Pregnancy Group of the Italian Society of Nephrology is to review the literature and discuss what is 
known about the clinical management of CKD after KT, with particular attention to women who start a pregnancy in non-
ideal conditions. While the experience in such cases is limited, the risks of worsening the renal function are probably higher 
in cases with markedly reduced kidney function, and in the presence of proteinuria. Well-controlled hypertension alone 
seems less relevant for outcomes, even if its effect is probably multiplicative if combined with low GFR and proteinuria. 
As in other settings of kidney disease, superimposed preeclampsia (PE) is differently defined and this impairs calculating 
its real incidence. No specific difference between non-teratogen immunosuppressive drugs has been shown, but calcineurin 
inhibitors have been associated with foetal growth restriction and low birth weight. The clinical choices in cases at high risk 
for malformations or kidney function impairment (pregnancies under mycophenolic acid or with severe kidney-function 
impairment) require merging clinical and ethical approaches in which, beside the mother and child dyad, the grafted kidney 
is a crucial “third element”.
Keywords Chronic kidney disease · Evidence-based medicine · Pregnancy · Hypertension · Proteinuria · Preeclampsia · 
Pre-term delivery
Introduction: an historical note
The history of pregnancy after kidney transplantation starts 
with young twin sisters: “In May, 1956, one of a pair of 
21-year-old identical twin females from Oklahoma was 
being studied as a potential recipient for a kidney transplant 
from her twin sister”. It is interesting to note that in this 
paper the family status was reported in the opening sen-
tences: “Both were childless, having been married for less 
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than a year.” The state of the recipient was defined as “dire” 
“with hypertension (blood pressure of 190 systolic, 120 dias-
tolic), congestive heart failure (…)” [1].
The paper reports that this woman regained her health, 
recovered her menstrual cycle and soon became pregnant, 
giving birth, by caesarean section, chosen for fear of renal 
compression, to a healthy baby. The donor and recipient 
were enthusiastic enough to give birth, as the paper reports, 
to a total of five babies, all of them in good health, at the 
time The New England Journal of Medicine paper was pub-
lished [1].
In 1966, Murray et  al. wrote in JAMA: “Medical 
advances force new judgments and evaluations. The ethics, 
legality, and morality of organ transplantation, a recent and 
still unpredictable therapeutic procedure, has already elicited 
editorials, special articles, and conferences (…)”, underlin-
ing the importance of maintaining what we now call quality 
of life, which was implicit in the job of a good physician, 
before measurement was attempted.
In this context it is worth quoting the paper entitled 
“Transplantation and haemodialysis. The recipient’s 
response to renal transplantation”, in which we read: “I 
guess, like other people, I never fully appreciated the sim-
ple things in life until I lost them. Just to be able to get up in 
the morning and go out and do a day’s work is a wonderful 
feeling (…)” [2].
When Edith Helm died, 55 years after having transplanta-
tion, leaving a son, a daughter, four grandchildren and four 
great-grandchildren, Professor Murray, who considered the 
sisters and their families part of “the extended Murray fam-
ily”, thanked her for her contribution to demonstrating that 
having a child after transplantation was possible. Besides 
eliciting admiration for the Nobel Prize winner, this story 
should also teach us the importance of curiosity and humil-
ity, and of personalised solutions in the management of 
pregnancy after kidney transplantation [3]. Not many years 
would pass before there were reports of successful pregnan-
cies after transplantation from non-identical twins and of 
vaginal deliveries [4, 5]. The era of pregnancy after kidney 
transplantation had begun [6–8].
Evidence‑based medicine and pregnancy 
after KT: methodological insights
Evaluating the evidence on pregnancy in kidney transplanta-
tion (KT) is dogged by many of the same methodological 
problems as that on pregnancy in chronic kidney disease 
(CKD) or in patients on dialysis [9–16]. A common lan-
guage is lacking, in particular for the definition of preec-
lampsia (PE), and for preterm delivery. The population is 
highly heterogeneous, and relatively few large studies are 
available; the periods of study are different and stratification 
is seldom attempted. Information on miscarriages is scant, 
and is usually limited to small single-centre series, due to the 
difficulties inherent in tracking the data on larger series or 
registries [17–26]. Hence, most systematic reviews and large 
series conclude by stating that more evidence is needed, and 
while we have data on “ideal patients”, less is known about 
patients with reduced kidney function, disease recurrence 
or proteinuria.
After kidney transplantation, as in all the CKD stages, the 
degree of kidney impairment, hypertension and proteinu-
ria are acknowledged factors in the pathogenesis of adverse 
pregnancy-related outcomes, even though their pathogenesis 
is incompletely understood [27–32].
Kidney function assessment in pregnancy is a challenge 
both after KT and in CKD: no validated formula exists and 
stratifications based upon serum creatinine, or serum cysta-
tin-C are not commonly employed [33–43]. Because there 
are so few randomized controlled trials (RCTs) and large 
observational studies, we will deal mainly with low levels 
of recommendation and not graded suggestions, so that in 
this paper we present what constitutes “best practice”, under-
lining the key role experience plays in supporting clinical 
choices [9, 10].
Evidence‑based medicine and pregnancy 
after KT: bioethical aspects
 (i) Pregnancy is not a “zero-risk” choice. Grading the 
risks of pregnancy after kidney transplantation is 
difficult, in particular in cases that differ from the 
“ideal” candidate (strong suggestion, evidence from 
different sources, mainly epidemiological studies).
 (ii) Pregnancy after KT poses important ethical problems 
(strong suggestion, beyond evidence).
 (iii) Pregnancy in “non-ideal” candidates after KT is an 
example of bioethical conflict, in which the princi-
ples of ethical assessment may give rise to contrast-
ing evaluations (strong suggestion, beyond evidence).
Pregnancy is not a “zero-risk” situation: in the general 
population, more than 10% of pregnancies are complicated 
by hypertensive disorders (including 3–5% of PE) or by ges-
tational diabetes [44–47]. All these events are more common 
in CKD, starting in its early stages, and this also applies to 
KT patients with normal kidney function [32, 48–51].
In the absence of a precise quantification of the risks 
across the scale of kidney function and proteinuria, it is dif-
ficult to define what an “acceptable risk” is for a pregnancy 
after KT [52–54]. In fact, with the excellent results of the 
first pregnancies after KT pregnancy became an option that 
gave rise to great expectations—the conviction that restoring 
fertility after a successful KT would be possible in a not too 
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distant future [1, 2, 4–6, 55]. As will be discussed below, 
the ideal candidate for pregnancy after KT is a woman with 
normal kidney function, no proteinuria, normotension, 
no recent acute rejection, good compliance and low dose 
immunosuppression, who has not taken potentially teratogen 
drugs [mycophenolic acid and mammalian target of rapamy-
cin (m-Tor) inhibitors] in the last months, and after at least 
1–2 years after transplantation.
One of the main issues in this context is the definition 
of “normal” or “good” kidney function: the classic CKD 
classification is not routinely used after kidney transplanta-
tion, and studies use different cut-points as for definition of 
normal or good kidney function [17–26].
There is no doubt that a glomerular filtration rate (GFR) 
above 90 ml/min defines a normal renal function; “good” 
renal function is usually defined as a GFR above 60 ml/
min, even if, at least according to the Italian experience, 
there may be significant differences between patients with 
GFR ≥ 90 ml/min and those with 60–90 ml/min of GFR [56].
Likewise, the definition of the cut-points for proteinuria 
and hypertension are non-univocal; while there is no doubt 
that, as well as in the overall population, blood pressure level 
below 130/80 is optimal and proteinuria in pregnancy is con-
sidered as normal when below 300 mg/day, there is a grey 
zone for blood pressure level below 140/90 and proteinuria 
below 300–500 mg/day [17–26, 56].
The Study Group therefore proposes an individualised 
evaluation in all cases with GFR (at best assessed by cre-
atinine clearance) below 90 ml/min, blood pressure above 
130/80 mmHg and proteinuria above 300 mg/day.
The literature reports few cases of pregnancy in the con-
text of malfunctioning KT, suggesting that counselling has 
systematically discouraged pregnancies in “less than ideal” 
conditions; therefore, risk assessment in a “failing” KT is 
presently difficult. Even if not quantified, these situations 
constitute a risk of developing severe hypertension, pro-
teinuria and prematurity, and of accelerating kidney failure 
[6–8, 32]. Hence, in the presence of strong determination to 
have a baby, the clinical decision must merge with an ethi-
cal approach.
Pregnancy in the context of “less than ideal” KT is an 
example of conflict between four main principles of medi-
cal ethics (autonomy, non-maleficence, beneficence, and 
justice). The benefit for a KT woman of having a baby is 
clear, and conflicts with the potential harm to the kidney 
graft, to maternal health and to the baby, who risks being 
born preterm, with potential consequences for its long-term 
health. None of these risks is however clearly quantifiable. 
The concept of distributive justice, that considers KT as a 
resource in contrast with decisions that could accelerate its 
loss, while ensuring the patient’s autonomy means that the 
final choice cannot be taken by a third party [55–59].
The hierarchy of ethical principles differs from one 
country to another. In Mediterranean countries, where 
the patient-physician relationship historically followed 
a paternalist model, the principle of primum non nocere 
supported the negative medical attitude towards pregnancy 
in less-than-optimal conditions. Conversely, in English-
speaking countries, where the patient’s self-determination 
is seen as paramount, autonomy comes first, and it is felt 
that it should be respected after ensuring that the patient 
has comprehended and accepted the risks her decision 
involves. The practice, observed in some transplant cen-
tres, of asking the patients to avoid pregnancy, as a way to 
optimize the social advantage of a successful transplanta-
tion, considers justice to be the leading principle [60–68].
There is no “right answer” in bioethics. However, the 
current ethical approaches, under the influence of Anglo-
American bioethics, privilege autonomy, a concept that is 
increasingly integrated in juridical recommendations. The 
paradigm shift from paternalism to self-determination and 
from non-maleficence to autonomy will probably lead to 
a more permissive attitude towards pregnancy after KT in 
less than optimal conditions.
What are the main adverse outcomes 
in pregnancy in KT patients?
 (i) The risk of maternal death is low and difficult to 
quantify (strong suggestion; scattered evidence).
 (ii) The risks of worsening kidney function are low in 
KT patients with normal kidney function, but have 
not been clearly quantified in other cases (moderate 
suggestion; scattered evidence).
 (iii) The risks to the foetus are mainly related to prema-
turity (strong suggestion; evidence from large obser-
vational studies and registries).
 (iv) Foetal malformations do not increase in KT patients, 
if teratogen drugs are avoided (strong suggestion, 
large body of evidence from different sources).
 (v) There is no substantial difference in outcomes 
between patients treated with non-teratogen drugs; 
calcineurin inhibitors may be associated with risk of 
foetal growth restriction (strong suggestion; indirect 
evidence from different sources).
 (vi) The risk of adverse maternal-foetal outcomes appears 
to be higher in multiple pregnancies (moderate sug-
gestion, few available data).
 (vii) The risk of adverse maternal-foetal outcomes appears 
to be higher in assisted-fertilization pregnancies 
(moderate suggestion, few available data).
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Maternal death is rare enough to represent a non-quan-
tifiable risk during or immediately after a KT pregnancy. 
The long-term risks are difficult to quantify and should 
probably be discussed in relation to pregnancy when coun-
selling dialysis patients [16, 69–73].
The risk of kidney function impairment is low in KT 
patients who start pregnancy with normal kidney function. 
The definition of normal kidney function is however not 
univocal, and is often based on creatinine levels and not 
on creatinine clearance or GFR [38, 39, 43].
As will be discussed below, the risks are higher in 
patients with reduced kidney function; this should be obvi-
ous considering the progressive impairment of the results 
seen in non-KT patients with CKD [13, 28, 30, 74–76].
New onset of proteinuria or increase of pre-existing 
proteinuria seems to be common; once more, the lack of 
standard criteria and the low use of 24-h proteinuria after 
KT make it difficult to assess the evidence [77].
Prematurity (defined as birth before 37 completed ges-
tational weeks), early preterm delivery (before 34 com-
pleted gestational weeks) and extremely preterm delivery 
(before 28 gestational weeks) increase in KT pregnancies 
and the increase is greater in KT patients with impaired 
kidney function. No graduation of the effect across stages 
is yet available.
Among the many risks linked to prematurity that should 
be addressed in counselling (perinatal death, retinopathy, 
and neurological problems) the possibility that premature 
babies are more likely to develop CKD and hypertension 
or cardiovascular diseases in adulthood should be dis-
cussed [78–94].
There is no evidence that children from KT mothers 
have a higher rate of malformations than the general popu-
lation, except for those linked to genetic diseases, such as 
congenital abnormalities of the kidneys and of the urinary 
tract (CAKUT) or autosomal dominant polycystic kidney 
disease (ADPKD) [17–21, 23, 56, 95–100].
Data on CKD and the general population suggest that 
multiple pregnancies have higher risks of adverse out-
comes [9, 101–105]. This should be kept in mind, espe-
cially for women receiving assisted-reproduction treat-
ment, which is becoming increasingly popular with KT 
patients, and in turn creates a higher risk of adverse preg-
nancy-related outcomes [106–109].
Few studies have been specifically addressed to the 
long-term health of the children of KT mothers. Based 
on the scant evidence available, it appears that most chil-
dren of KT mothers attain normal developmental goals. 
However, the neurological problems linked to prematurity 
should not be underestimated and must be explained at 
counselling [73, 78–94, 110–113]. The Study Group feels 
there is a clear need for further long-term studies focussing 
on the psychosocial health of these children and on their 
intellectual development.
Which patients are the “best candidates” 
for pregnancy after KT and which patients 
are not?
 (i) The following are the requirements most often cited 
for identifying the best candidates for pregnancy 
after KT from the clinical point of view:
(a) Normal or good kidney function (differently 
defined: usually as above 60 ml/min)
(b) No proteinuria or scarce proteinuria (differently 
defined: usually as below 300–500 mg/day)
(c) No hypertension or well-controlled hypertension 
(the latter usually defined as treated in monother-
apy and without organ damage)
(d) Low-dose immunosuppression with “allowed” 
drugs
(e) At least 2 years after KT (this interval has recently 
been reduced to 1 year after KT) (strong sugges-
tion, several sources of observational data).
 (ii) Further clinical maternal elements that can contribute 
to identifying the “best candidates” include:
(a) No recent rejection episode
(b) No recurrent urinary tract infection
(c) Discontinuation of potentially teratogen drugs 
for at least 6 weeks (moderate suggestion, several 
sources of observational data and indirect evi-
dence).
 (iii) From the obstetric point of view, besides the absence 
of hypertension, and kidney disease, a low-risk 
mother is young (under 35), non-obese, non-diabetic, 
with a spontaneous singleton pregnancy (strong sug-
gestion, several sources of observational data and 
indirect evidence)
 (iv) All other cases are high-risk KT pregnancies. No 
graduation of risks is presently available (strong 
suggestion, several sources of observational data and 
indirect evidence).
Identification of the best candidates for pregnancy after 
KT is based on the results of observational studies [17, 32]. 
Overall, KT pregnancy risks display behaviours similar to 
those found in CKD pregnancies, and the best results are in 
patients with normal kidney function, normotension and no 
proteinuria [9, 17, 30, 32, 51, 56, 114–120].
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On account of its patients’ characteristics, the transplant 
world has remained impermeable to the CKD staging system 
and the definition of “normal” kidney function is usually 
based upon serum creatinine, with different cut-points in 
different studies. The relationship between kidney function 
and pregnancy outcomes is not surprising, and is probably 
the first item to take into account in a risk assessment. How-
ever, no graduation of risks is available and the Study Group 
suggests, in the absence of new data, applying the same cri-
teria that have proven to be efficacious in CKD (stratification 
along the classic CKD stages) [9, 11, 30, 56, 121].
Hypertension and proteinuria are identified as independ-
ent risk factors for adverse pregnancy outcomes [30]. How-
ever, as no study has tested their combined effect, the Study 
Group suggests basing counselling on the wider set of data 
on CKD pregnancies, in which the presence of hypertension 
and proteinuria exert a multiplicative effect on the risks. KT 
patients with hypertension and proteinuria should therefore 
be informed of the high incidence of preterm delivery in 
CKD patients with both hypertension and proteinuria, even 
in those with normal or near normal kidney function [30, 
50, 122].
Immunologic stability is another must. This includes 
being rejection-free for at least 6 months (some studies do 
not define the interval and in others the length of time ranges 
from 6 months to 1–2 years), and being treated with low-
dose immunosuppression. There were several studies that 
indicated that pregnancy was safer at least 2 years after KT; 
however, recent studies suggest that waiting for 1 year can 
lead to superimposable results [123–128]. A few reports of 
pregnancies immediately after KT or of KT during the early 
weeks of pregnancy indicate that success is also possible in 
these cases, warning against systematic pregnancy termina-
tion in such occurrences [129, 130].
As previously stated, a GFR above 90 ml/min, a blood 
pressure at or below 130/80 mmHg and proteinuria infe-
rior to 300 mg/dl clearly defines an ideal situation. A grey 
area includes GFR 60–90 ml/min, blood pressure below 
140/90 mmHg and proteinuria below 500 mg/day [17–26, 
56].
The Study Group therefore proposes an individualised 
evaluation in all these cases.
The relationship between acute rejection and pregnancy 
is complex. This is a situation which calls to mind the rela-
tionship between pregnancy and flares in systemic lupus 
erythematous: in the past flares were considered frequent, 
while when they were subsequently re-dimensioned, this led 
to abandoning the policy of administering bolus steroids at 
or immediately after delivery [9, 131].
A pregnant grafted woman has been defined as a complex 
chimera with at least three cell populations: her own ones, 
the donor organ, and the foetus. Previous pregnancies and 
blood transfusions may have added other cell populations. 
The tolerance system is complex and not all antigens induce 
a response; tolerance may be the result of exposure of par-
ticular antigens or complexes [132].
The postpartum period is also of pivotal importance: the 
acute loss of the placenta, which was a primary driver of 
tolerance, could theoretically trigger rejection, while the 
decrease of interleukin (IL)-10 and estrogen levels may 
counterbalance this effect [132, 133]. Acute kidney injury 
(AKI) is a relatively unexplored syndrome post-partum, and 
new data suggest in particular to pay attention to the use of 
anti-fibrinolytic agents [134].
While recent epidemiological studies are reassuring con-
cerning the risk of rejection, the Study Group feels it is vital 
to take into account the clinical impression that acute rejec-
tion during pregnancy or in puerperium can be particularly 
aggressive. While more experience-based than evidence-
based, this consideration should suggest maintaining a high 
level of attention in these delicate moments of a woman’s 
life [17, 23, 24, 26].
Urinary tract infections are frequent in KT pregnancies; 
once more, the recent literature is scant. However, consid-
ering the experience in CKD pregnancies, the Study Group 
suggests maintaining a policy of high attention, and per-
forming a urinary culture at least twice monthly, as coun-
selled for CKD women with a history of upper urinary tract 
infections, kidney malformations or kidney scars [9, 135, 
136].
Table  1 shows the main immunosuppressive drugs 
employed in pregnant KT patients. Azathioprine, cyclo-
sporine, tacrolimus and steroids are considered safe 
[137–154]. Little is known about m-Tor inhibitors, but 
since they are teratogen in animals, they are avoided in 
humans, even if a few cases with a positive outcome have 
been recently reported in the literature [137–139]. Since 
mycophenolate can cause a characteristic embryopathy, 
known as MMF foetal syndrome, this drug should be dis-
continued at least 6 weeks before conception [123, 125, 
140–152].
While several studies focus on the effect of kidney func-
tion on pregnancy outcomes, less is known on the additive 
effect of the classical risk factors on KT pregnancies [153].
High maternal age increases the risk for preterm deliv-
ery and PE. Obesity is associated with a higher risk of the 
hypertensive disorders of pregnancy; the same is true for 
diabetes, which is also associated with congenital malforma-
tions, often at the cardiac level [17, 49, 154–156]. The risks 
are higher in type-1 diabetic mothers. The effect of assisted 
fertilization and multiple pregnancies, also associated with 
adverse pregnancy outcomes, will be further discussed 
below [157–159].
Acknowledging these knowledge gaps, the Study Group 
underlines the need for further studies targeting pregnancies 
in “non-ideal” KT pregnancies.
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Frequency and modality of controls in KT 
pregnancy
Follow-up should be intensified in KT patients as com-
pared with normal pregnancies (strong recommendation, 
indirect evidence)
The main goals of follow-up are early identification 
and treatment of complications, including acute rejection, 
hypertension, anaemia, coagulation disorders, and timely 
planning of delivery (strong recommendation, indirect 
evidence)
No validated formula for GFR calculation in KT preg-
nancy is available, hence GFR should be assessed by 24-h 
urine collection (strong recommendation, based on GFR in 
normal pregnancy and PE)
By analogy with follow-up in pre-RRT CKD stages, fol-
low-up should be intensified in KT patients with reduced 
kidney function, hypertension and proteinuria (strong rec-
ommendation, indirect evidence).
Follow-up should include at least one nephrology consul-
tation with blood and urinary tests every 2–4 weeks in non-
proteinuric, non-hypertensive KT patients with “good” kid-
ney function; the frequency of controls should be increased 
in the case of proteinuria, hypertension or reduced kidney 
function (strong recommendation, indirect evidence).
Pregnancy after KT should be considered as “at high 
risk”, even in the presence of the “ideal” profiles deline-
ated above, and the Study Group suggests increasing the 
frequency of controls in proportion to the decrease in kidney 
function, based on the presence of hypertension, proteinuria, 
urinary tract infection or any other risk factor; particular 
attention should be paid to the side effects of antirejection 
therapies (Table 1).
The flow charts, adapted from the position statement on 
CKD and pregnancy, summarize the proposed frequency of 
controls (Fig. 1) [9].
The Study Group suggests a minimum requirement of 
one nephrology control with blood and urinary tests every 
2–4 weeks in patients with “good” kidney function (in the 
absence of clear definitions, we consider this group to be 
women with at least 60 ml/min of creatinine clearance meas-
ured on 24-h urine collection), and without proteinuria and 
hypertension, increasing to weekly controls in patients with 
any combination of the risk factors mentioned above.
The assessment of kidney function is especially challeng-
ing in KT pregnancies. Little is known about the role of 
Table 1  Main immunosuppressive drugs for chronic treatment in pregnant KT patients (modified from reference [9])
FDA rating [135]: A, controlled human studies show no risk; B, no evidence of risk in studies; C, risk cannot be ruled out; D, positive evidence 
of risk; X, contraindicated in pregnancy
KT kidney transplantation, FDA US Food & Drug Administration, KDIGO kidney disease-improving global outcomes
Drug Main features FDA rating
Usually considered as safe
 Azathioprine This is the most widely used immunosuppressive drug. It is teratogen in animal models, but not in 
humans, possibly because the foetal liver is not able to activate the drug. KDIGO and European Best 
Practice Guidelines suggest switching from mycophenolate to azathioprine before pregnancy
D
 Cyclosporine A This calcineurin inhibitor has not been associated with increased teratogenicity; however, small for 
gestational age babies and preterm delivery have been reported, possibly due to the maternal disease 
and not specifically to the drug. Levels may vary in pregnancy and the hypertensive, hyperglycaemic 
and nephrotoxic effects should be mentioned
C
 Tacrolimus The drug has similar effects and side effects to cyclosporine A; experience is more limited than with 
the previous drug
C
 Steroids Together with azathioprine these are the most often employed and best known drugs. The most fre-
quently used short-acting corticosteroids include prednisone, methylprednisolone and prednisolone, 
while betamethasone and dexamethasone are among the long-acting drugs. No major malformations 
have been reported, and the issue of labiopalatoschisis is debated. A higher risk of premature rupture 
of membranes has been reported. Other relevant side effects include infectious risk, and the increased 
risk of gestational diabetes
C
To be avoided
 Mycophenolate Severe foetal malformations are reported, mainly involving cardiovascular and cranial malformations. 
Discontinuation for at lest 6 weeks, to stabilize kidney function, is usually indicated after kidney 
transplantation
D
 m-Tor inhibitors Very few studies have considered their use in pregnancy. They are teratogenic in animals and discon-
tinuation in humans is a matter of debate. KDIGO guidelines suggest discontinuation in anticipation 
of pregnancy
C
 Rituximab, simulect Too few studies to allow safe use in pregnancy. Need for further evidence, but trials are unlikely to be 
undertaken
C, D
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hyperfiltration, an increase in plasma volume and in volume 
distribution; validated GFR formulae are not available (a 
problem shared by all CKD stages), and creatinine clearance 
on 24-h urine collection is not frequently employed; similar 
considerations apply to proteinuria [160, 161]. Therefore, 
in the absence of agreed assessments, the Study Group con-
siders it wise to refer to the same gold standard identified 
for CKD patients (based on 24-h urine collection for both 
creatinine clearance and proteinuria).
An important issue is probably also the presence of the 
physiological decrease or of an increase of serum creatinine 
in pregnancy. Once more, there are no specific data in this 
regard, but according to the clinical experience the Study 
group underlines the importance of paying attention to the 
presence-absence of physiological increase in the kidney 
function as a potential predictive element of pregnancy out-
comes after KT.
The issue of an increase in extracellular volume is 
important and is probably one of the reasons for the 
frequent need to increase doses of the calcineurin inhibi-
tors. The higher need for anti-rejection drugs is probably 
multifactorial as many patients need to at least double the 
initial doses prescribed, despite the fact that distribution 
volume is usually only about 30% higher (Table 1).
KT patients are at risk for urinary tract infections; 
therefore, urinalysis and urinary cultures should be a part 
of routine controls, and the frequency should be increased 
to weekly in patients with recurrent urinary tract infections 
during or before pregnancy (Fig. 1).
These considerations balance time-consuming assess-
ments (24-h urine collection, frequent urine and/or blood 
tests) with the need for close control of the mother, foetus 
and grafted kidney, using simple, non-invasive procedures. 
The Study Group underlines that these recommendations 
are based mainly on scattered evidence and common 
clinical understanding. Further economic evaluations and 
organisational analyses are highly recommended.
Main biochemical
tests prescribed 
Other
Imaging
Minimal follow-up
KT Pregnancy (staging upon 24-hour urine collecon)
Stage 1
2-4 weeks
urinalysis, urinary culture, Na, 
K, Ca, P, Albumin, Creanine, 
Urea, Uric acid; Clearance and 
proteinuria on 24-hour urine 
collecon
Urinalysis and cultures every 
1-4 weeks
Renal ultrasounds if 
not performed in the 
previous year
Nutrional 
parameters at start: 
ferrin, vit D, B12, 
folates, Albumin, 
Total proteins
Like stage 1
Like stage 1
Like stage 1, every 
10-12 weeks
Like stage 1; at least 
monthly 24-hour urine 
collecon
Like stage 1
Like stage 1; monthly 
in on-diet paents
Like stage 1;  24-hour 
urine collecon twice 
monthly
Like stage 1
Like stage 1; monthly 
in on-diet paents
Stage 2 Stage 3 Stage 4
2-4 weeks 1-3 weeks 1 – 2 weeks
Drug Levels
It is recommended that immunosuppressive drug levels be monitored at lest twce
monthly at pregnancy start and at least monthly aerwards.
Dosage adjustments may be necessary
Fig. 1  Proposed frequency of controls during pregnancy according to CKD stages in women with a kidney transplantation
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Treatment of hypertension in KT pregnancy
Pre-existing hypertension should be managed like chronic 
hypertension in CKD women, with careful monitoring, 
avoiding overcorrection (strong recommendation, indirect 
evidence and scattered data).
Hypertension occurring in pregnancy, with or without 
proteinuria, should be differentiated from PE, on account 
of the different prognosis for the two conditions in preg-
nancy (moderate recommendation, indirect evidence and 
scattered data).
Low-dose acetylsalicylic acid can be employed in the 
prevention of PE, in patients without contraindications, as 
in other high-risk pregnancies (moderate recommendation, 
indirect evidence and scattered data).
Blood pressure targets in hypertensive KT pregnancies 
have not been established, similarly to what was observed 
in CKD pregnancies [9, 13]. Learning from data available 
on pregnancies in chronic hypertension, overcorrection 
should be avoided, given its detrimental effects on foetal 
growth [162–171].
In keeping with the indications for CKD pregnancies, on 
the basis of the results of the large Control of Hypertension 
In Pregnancy Study (CHIPS) trial, our group suggests 
implementing strict blood pressure control (“ideal” tar-
get < 130/80 mmHg, acceptable < 140/90 mmHg), under 
careful clinical surveillance [9, 168].
As reported in Table 2, no anti-hypertensive drug is 
labelled as fully safe in pregnancy. Most importantly, the 
teratogenicity of angiotensin-converting enzyme inhibi-
tors (ACEi) and angiotensin II receptor blockers (ARBs) is 
still a matter of debate; therefore, the Study Group strongly 
supports pre-emptive discontinuation of ACEi and ARBs 
in patients without proteinuria, and early discontinuation at 
the first positive pregnancy test (4th–6th gestational week) in 
patients in whom proteinuria is considered a potential threat 
for kidney function [9, 171–176].
The differential diagnosis between hypertension and pro-
teinuria due to recurrence of the original disease, chronic 
allograft nephropathy or reduced nephron mass and PE is 
clinically important, since the maternal-foetal prognosis is 
worse in the latter [177–179].
Uric acid levels are well known markers of risk of adverse 
pregnancy outcomes in pregnancies in the overall popula-
tion; there are limited data after kidney transplantation, 
suggesting that low pre-conception uric acid levels are cor-
related with positive pregnancy outcomes, but their role as 
Table 2  Commonly needed drugs in pregnant patients with kidney transplantation (modified from reference [9])
FDA rating: A, controlled human studies show no risk; B, no evidence of risk in studies; C, risk cannot be ruled out; D, positive evidence of 
risk; X, contraindicated in pregnancy
RCOG Royal College of Obstetricians and Gynaecologists, AIPE Associazione Italiana Preeclampsia, ACEi angiotensin-converting enzyme 
inhibitors, ARBs angiotensin II receptor blockers. For other abbreviations, see Table 1
Drug Anti-hypertensives FDA rating
Usually considered first choice
 Alpha-methyl dopa Widely used, with no reported negative effects on the foetus or on its subsequent 
development. May not be able to correct severe hypertension
B
 Niphedipine The long-acting drug most commonly used in pregnancy. The increase in peripheral 
oedema may be a relevant side effect in CKD patients
C
 Labetalole Usually well tolerated, should be avoided in subjects with asthma. In a RCT it was 
shown to be comparable to alpha-methyldopa
C
Usually considered second choice
 Beta blockers The main drawback was foetal growth restriction. Atenolol (D) often involved. May 
be effective in severe hypertension. May induce hypoglycaemia, hypotension and 
bradycardia at delivery
B Pindolol
C Metoprolol
D Atenolol
 Clonidine Side effects and rebounds at discontinuation are common. Slowing foetal growth also 
reported
C
 Alpha blockers Other drugs should be preferred since controlled studies are missing C
 Diuretics Usually avoided. Thiazides may be continued. Amiloride may be employed in Gitel-
man syndrome
B
Hydrochlorothiazide
Amiloride
To be avoided
 Short-acting niphedipine Contraindicated by FDA, RCOG and AIPE due to the risk of severe sudden hypoten-
sion with detrimental effects on placental flows
D
 ACEi
ARBs
Risk of major malformations, in particular in the second and third trimester C 1st trimester
D 2nd 3rd trimester
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biomarkers is not confirmed after kidney transplantation 
[180].
Among the biomarkers of PE, the ratio between solu-
ble Fms-like tyrosine kinase 1 (sFlt-1), a receptor for both 
vascular endothelial growth factor (VEGF) and placental 
growth factor (PIGF) is of high interest at least in ruling out 
the severe forms of PE [181–184]. The role of these bio-
markers in the differential diagnosis between PE and CKD 
is still under study, and the Study Group recommends using 
the test, when available, in support of clinical reasoning [9].
Management of proteinuria in KT pregnancy
Evidence on pregnancy in KT patients with proteinuria is 
limited, hence the main suggestions are derived from the 
broader experience with CKD patients (medium recommen-
dation, indirect evidence)
Low-dose acetyl salicylate is indicated in proteinuric 
patients (as well as in patients with reduced kidney function 
or hypertension) (strong recommendation, different levels of 
evidence in various diseases)
Efforts should be made to counterbalance hyperfiltration: 
while albumin infusion should be avoided, moderate protein 
restriction can be attempted (medium recommendation, indi-
rect evidence)
Low-dose acetyl salicylate (ASA) for the prevention of 
PE is suggested by a large body of evidence; all KT patients 
share an increased risk of PE, higher in patients with protein-
uria or hypertension [185–193]. The best timing for starting 
ASA is debated; the Study Group suggests that ASA should 
be continued in pregnancy if already part of the chronic 
treatment. In the case of ASA start, early start (at positive 
test) to favour placentation or later start (2nd trimester) to 
minimise bleeding risks in the case of miscarriage, should 
be discussed within the multidisciplinary team [9].
Two recent meta-analyses suggest that early ASA use 
(start before 16 weeks) is associated with better outcomes, 
but the dose is different in the two studies and the effect is 
only significant as for prevention of early PE, which is prob-
ably less frequent in transplanted, as well as CKD women, 
than “late-maternal” PE [192, 193].
Due to the pathophysiological importance of hyperfiltra-
tion in long-term kidney damage, the Study Group suggests 
avoiding, whenever possible, treatments which potentially 
increase hyperfiltration, such as albumin infusion [194].
Although we lack robust evidence on the advantages of a 
moderate protein restriction, often suggested in other forms 
of CKD, the Study Group recommends avoiding protein-
rich diets, and considering the potential of this nutritional 
approach at least in cases in which hyperfiltration is thought 
to play an important role, in keeping with what is advised in 
CKD [9, 195, 196].
Management of KT pregnancy with reduced 
kidney function
Evidence on pregnancy in KT patients with reduced kid-
ney function is scant, probably as a result of the policy of 
discouraging pregnancy in this context (medium recom-
mendation, indirect evidence)
Given the lack of data grading the effect of reduced kid-
ney function in KT pregnancy, counselling and manage-
ment should be based on the experience in CKD (strong 
recommendation, indirect evidence)
There is no indication on when to start dialysis in preg-
nancy in the setting of a failing KT. This knowledge gap 
should be considered in counselling (strong recommenda-
tion, indirect evidence).
Evidence on pregnancy when there is a failing KT is 
extremely limited, differently from the growing body of 
evidence on pregnancy in the most advanced CKD stages 
in native kidneys. The most likely explanation is that this 
is an indirect effect of discouraging pregnancy in “less 
than optimal” conditions after KT [197].
As previously discussed from the bioethical point of 
view, the growing importance attributed to patients’ auton-
omy will probably modify this situation, but our lack of 
data makes precise counselling difficult, and points to bas-
ing advice upon the larger body of data available on native 
kidneys. In this regard, the Study Group would like to refer 
to the previous “best practice” on pregnancy in CKD [9].
A particular aspect, not fully clarified even in non-
pregnant KT patients, regards when to restart dialysis in 
a failing KT. Bearing in mind this lack of evidence and 
acknowledging the experience in the non-pregnant popula-
tion and the most recent guidelines, the Study Group sug-
gests adopting individualised policies, based upon clinical 
judgement and not on GFR only, in agreement with what 
was previously discussed in CKD [9].
Management of inadvertent pregnancy 
under potentially teratogen agents, 
or undertaken “too early”
The most important potentially teratogen agent employed 
after KT is mycophenolate mofetil (MMF), whose use is 
associated with severe malformations, mainly skeletal and 
ocular ones, and with mental retardation (strong recom-
mendation, scattered data)
The severity of the syndrome is variable and MMF treat-
ment is also compatible with apparently normal develop-
ment. The reasons for the syndrome’s different presentation 
are not known (strong recommendation, scattered data)
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Physicians of women under MMF should be aware that 
they need to interrupt treatment at least 6 weeks before a 
patient becomes pregnant (strong recommendation, scat-
tered data)
Other potentially teratogen drugs (m-TOR inhibitors, 
ACEi and ARBs) have less clear risk patterns and probably 
have a lower incidence of malformations (strong recom-
mendation, scattered data)
The issue of pregnancy occurring “too early” merges 
the frequent use of contraindicated drugs and higher 
immunological risks (strong recommendation, scattered 
data)
The caregiver multidisciplinary team should support the 
patient’s choice to continue or terminate pregnancy, offer-
ing careful counselling and making use of imaging to detect 
major foetal abnormalities (strong recommendation, indirect 
data)
When pregnancy is undertaken early in the course of 
transplantation or is unexpected, the use of drugs that are 
contraindicated (such as MMF), or for which there is a rea-
sonable doubt of teratogenicity (such as ACEi, ARBs and 
m-TOR inhibitors), poses clinical and ethical problems. The 
issue of timing for discontinuation before elective pregnancy 
is still open; consensus is now on discontinuation of MMF 
and enteric coated mycophenolate sodium (EC-MPS) at least 
6 weeks before attempting conception; mTOR inhibitors 
should also be discontinued or replaced before pregnancy 
is attempted, even if positive reports are available (Table 1).
The most important problem occurs when pregnancy is 
unexpected and conception has occurred while the patient 
was on these treatments; in fact, none of these drugs is a 
cause of malformations in 100% of cases, thus leaving space 
for individual choice. While ultrasounds are increasingly 
able to detect major skeletal and organ malformations, some 
relevant malformation is not detectable, or is first seen in 
phases in which pregnancy interruption is no longer pos-
sible [198].
In the absence of potentially teratogen drugs, the classic 
contraindication to pregnancy in the first 2 years after renal 
transplantation is based upon the clinical assumption that 
the risk of acute rejection, graft dysfunction, and infection 
are higher than in the subsequent period. The empiric limit 
of 2 years has recently been challenged, suggesting that out-
comes may level after the first year of KT, thus widening the 
“ideal” timing, also taking into account that kidney function 
is usually better in the first years after kidney transplantation 
[125, 126].
In this regard, the Study Group suggests that conception 
should be avoided in the first year after KT. The best con-
traception treatment is still a matter of debate and a further 
best-practice paper will be dedicated to this issue. In the lack 
of evidence, the Study Group suggests a tailored approach be 
adopted, taking age, kidney function, risk of infection, renal 
disease and coagulation derangements into account [128, 
199–203].
In the case of “early” conception, i.e. in the first year after 
KT, in the absence of teratogen drugs, the Study Group does 
not support a policy of systematic pregnancy interruption, but 
once more suggests a personalised policy that considers the 
increased risk of graft dysfunction, and the likelihood of there 
being a further pregnancy in a “safer” period, based on consid-
erations such as the patient’s age and, if possible, information 
on her ovarian reserve.
Management of KT patients with multiple 
gestations
Multiple gestations, whether spontaneous or occurring as a 
result of assisted fertilization procedures, are at higher risk for 
adverse pregnancy-related outcomes (strong recommendation, 
indirect data)
There are few data on multiple pregnancies after KT and the 
ones we have are probably affected by reporting and publica-
tion biases. Within these limits, it seems that good outcomes 
are possible and may be the rule (medium recommendation, 
indirect data)
There is no need to interrupt multiple-gestation pregnancy 
in KT; however, follow-up should be intensified and an expert 
on the clinical management of multiple gestations should be 
included in the team (strong recommendation, indirect data)
In the general population, multiple gestations, whether 
spontaneous or occurring as a result of assisted fertilization 
procedures, are at higher risk for adverse outcomes [101, 
157–159]. A similar increase in risk has been described in 
pregnancies occurring in CKD patients, although the amount 
of data is limited, and there is probably a reporting and publi-
cation bias, leading to over reporting of favourable outcomes 
with respect to unfavourable ones. The current evidence only 
allows us to state that good outcomes are possible and may 
even be the rule, thus indicating that there is no reason for 
pregnancy termination in “ideal candidates”. However, follow-
up should be intensified and an expert on the clinical manage-
ment of multiple gestations should be included in the team. 
Patients in less than ideal situations should be warned both 
about the absence of elements allowing precise risk assess-
ment, and the fact that outcomes are less favourable in multiple 
pregnancies, whether or not these have resulted from assisted 
fertilization procedures [101–103, 105].
Advising KT patients who want to undergo 
assisted fertilization procedures
Assisted fertilization in the general population has a higher 
risk of PE, intrauterine growth restriction, and prematurity 
(strong recommendation, observational data)
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Assisted fertilization procedures are feasible in KT 
patients, but the evidence is scant and affected by reporting 
and publication biases. Within these limits, good outcomes 
are reported virtually with all techniques, but the incidence 
of adverse events is not known (strong recommendation, 
indirect data)
In the case of pregnancy after assisted fertilization tech-
niques, follow-up should be intensified and experts should be 
included in the team (strong recommendation, indirect data)
Assisted fertilization is increasingly chosen in the gen-
eral population, to overcome the limits imposed by age 
and chronic diseases. All these techniques are associated 
with higher risk of PE, intrauterine growth restriction, and 
prematurity; the risks increase with the need for in vitro 
manoeuvres, reaching a peak for egg donation. According 
to an increasing number of reports, mainly based on single 
cases, assisted fertilization procedures are feasible in KT 
patients, but the evidence is scant and there are likely to be 
important reporting and publication biases, leading to over-
reporting of successful cases [106–108]. Within these limits, 
good outcomes after KT are reported when using virtually 
all techniques, but the incidence of adverse events is not 
quantifiable on the basis of the present state of evidence, as 
only one relatively large series was found by our extensive 
search strategy [108].
Since assisted fertilization techniques are associated with 
a significant increase in adverse events in the general popula-
tion, the Study Group urges that follow-up be intensified and 
experts in the field be included in the multidisciplinary team 
in KT pregnancy after assisted fertilization.
While, given the present state of the art, the Study Group 
does not feel that nephrologists should encourage or discour-
age these procedures, our position is that while we support 
the choice of the mother-to-be, we should counsel tech-
niques that are more likely to lead to a single rather than to 
a multiple pregnancy. Due to the complexity of this problem, 
the Study Group plans to discuss it in a further dedicated 
best-practice review.
Pregnancy in kidney‑pancreas 
transplantation: specific issues
Solid-organ-transplant recipients should be considered high-
risk patients for pregnancy (strong recommendation, indirect 
data).
In pancreas-kidney transplantation (PKT) the presence of 
two organs in the pelvis poses additional risk to both mother 
and newborn (strong recommendation, indirect data).
The pancreas graft probably presents fewer complica-
tions during pregnancy in the presence of normoglycaemia 
(medium recommendation, scant data).
Birth weight and gestational age are usually lower when 
compared to KT (strong recommendation, registry data).
An integrated multidisciplinary team including a trans-
plant physician, nephrologist, diabetologist, and obstetrician 
is essential in counselling and follow-up (strong recommen-
dation, indirect data).
In the case of PKT, as in all solid-organ transplantation, 
recipients should be considered high-risk for pregnancy and 
management should be carried out by a multidisciplinary 
team, including a diabetologist, even in the presence of nor-
mal glycaemic levels. In fact, in PKT recipients the presence 
of two organs in the pelvis poses an additional risk to both 
mother and newborn [8, 204]. The risks are miscarriage, 
preterm birth, foetal malformation, preeclampsia, deteriora-
tion of renal function, and pancreatitis of the graft, reported 
even after uncomplicated delivery [205–207].
The pancreas graft probably presents fewer complications 
during pregnancy in the presence of normoglycaemia and, 
as in all cases of solid-organ transplantation, the risks are 
reduced if the pregnancy is planned, and if the organs are 
functional. As in the case of KT, the suggested timing is at 
least 1 year after transplantation with normal blood pressure, 
absent proteinuria and stable doses of immunosuppressive 
drugs.
Registry data indicate that mean birth weight and gesta-
tional age are lower when compared to kidney-only recipi-
ents, but the reasons for this are still a matter of debate [207].
For these reasons, the Study Group suggests that preg-
nant PKT mothers should be monitored very closely, indica-
tively every 2 weeks, during pregnancy. A fully integrated 
multidisciplinary team, including a transplant physician, 
nephrologist, diabetologist, and obstetrician is essential for 
counselling and in the follow-up of PKT pregnancy.
Working conclusions
Pregnancy is an added value for women with kidney trans-
plantation; fertility is at least partly restored and a success-
ful pregnancy is possible, frequent, and usually successful. 
However, KT pregnancies have a higher risk of PE, preterm 
delivery and small for gestational age babies than pregnan-
cies in the general population.
The profile of the “best” candidate for pregnancy after KT 
is relatively well drawn (normal or “good” kidney function, 
usually considered as a GFR above 60 ml/min), normoten-
sion or well controlled hypertension (one drug only, in the 
absence of end-organ damage), no proteinuria (or proteinuria 
below 300–500 mg/day), no recent rejection episode, and 
conception at least 1 year after KT. Definitions are how-
ever not always univocal, and less is known about “non-
ideal” candidates, who pose important clinical and ethical 
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problems in the complex interaction between the “best 
choice” for the mother, for the child and for kidney function.
Thanks to the progress in KT therapies, to improvements 
in the management of high-risk pregnancies, to the grow-
ing importance of patients’ self-determination, and to new 
options, such as assisted fertilization, the panorama of preg-
nancy after KT is changing.
The side effect of this positive outlook is that evidence is 
heterogeneous and sometimes difficult to interpret. This lack 
of certitudes should be borne in mind at counselling, and 
strongly supports shared choices in the context of multidis-
ciplinary care, as well as individualised approaches. Neph-
rologists need continuous updating in this emerging field, 
and once more the Study Group supports the establishment 
of educational programs and of multicentre research studies.
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